The bioavailability and the bioreactivity of the carcinogenic heterocyclic amine [2-'4CJ2-amino-1-methyl-6phenyl-inidazo [4, have been investigted d a dose a in that likluy from thehuman diet by accelerator mass spectrometry (AMS). [2-_4CJPhIP mus administered to mice at a dose equivalent to the consumption of two 100 g beef patties (41 ng/kg). The biological halflife of PhIP was 1 hr, with 90% ofthe dose being excreted via the urine. Peak tissue PhEP concentrations were reached within 3 hr, with the highest levels in the tissues ofthe gastrointestil tract, followed by the liver, kidney, pancreas, and thymus. Since the detection limit by AMS is dependent on the natural abundance of 14C, we have achieved further increases in sensitivity by producing mice that have 20% ofthe naturl abundance of 14C. Use of these 14C-depleted aniS all Ms rementS to be made near the natural lvel ofexore for many environmental carcinogens. PhIP-DNA adduct levels havealso been measured by 32P-postlabeling at doses of 1.0 , and 20 mg/kg.
Introduction
Determining the cancer risk that chemicals pose to humans has proven to be a difficult task. Biomarkers play an integral role in this process because theoretically they indicate progress in the development of disease, but the biomarkers must be selected to validly represent the disease mechanism (1) . Fundamentally at issue is the relationship between the delivered dose and the innate ability ofan organism, both on a systemic and cellular level, to cope with the challenge. In a practical sense, translating the carcinogenic response from high-dose animal studies to lowdose human exposure scenarios is the immediate concern from the standpoint ofa) developing valid biomarkers ofexposure and effect, b) for understanding mechanisms, and c) for risk assessment.
Heterocyclic Amines Our approach to this problem has been to focus on the DNA adduct as a potential biomarker for both exposure and effect, and we are using the high sensitivity offered by accelerator mass spectromery (AMS) for assessing adduct dosimetric relationships. AMS is a low-energy nuclear physics technique developed for measuring cosmogenic isotopes such as 14C and is ideal for studying the low-level dosimetry of isotopically labeled xenobiotics (4, 5) . AMS isolates and counts specific nuclei as opposed to measuring atomic decay. Thus, AMS methodology results in a 106-fold improvement in isotope detection efficiency compared to scintillation counting for 'C and has allowed us to quantitatively measure DNA adduct levels on the order of 10 -1I to 10 -12 adducts/nucleotide (6) . We also have applied the 32p_ postlabeling assay to mechanistic studies of the effects of these carcinogens on DNA. The postlabeling assay is a highly sensitive with N-hydroxy-PhIP in the presence of mouse hepatic cytosol as described in Buonarati et al. (9) . DNA from the tissues and in vitro incubations were isolated and 32P-postlabeled as described previously (9) . assay for DNA adduct detection that includes chromatographic separation ofspecific adducts and thus is quite useful for studying mechanisms of adduct formason and repair. Here we describe the fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-bipyridine (PhIP) at a dose equivalent to the consumption of200 g cooked meat and on the formation ofPhIP adducts at higher doses.
Results
PhIP was rapidly absorbed at the 41 ng/kg dose and maximal blood levels were reached within 0.5 hr (Fig. 1) . Excretion was equally rapid. Ninety percent of the administered dose was eliminated via the urine and 10% via the feces over the 96-hr period. The systemic half-life of the compound was 1 Maximal concentrations of PhIP were attained in the tissues between 0.5 and 3 hr after exposure, shown in Figure 2 . The highest tissue levels of PhIP or its metabolites were found in the stomach and intestine, followed by the liver, kidney, and pancreas. Some of the PhIP Ibund associated with the stomach may have been due to adsorption ofthe unabsorbed compound from the lumen surface of the tissue. PhIP levels in the tissues 96 hr after exposure were 0.5-2% of the administered dose. The residual levels of PhIP in the tissues were due possibly to covalent binding of active metabolites to DNA and protein and are currently under study.
Sensitivity of AMS
The absolute sensitivity limit for biological specimens is imposed by the natural 14C abundance present in all biological material (Fig. 3) . The absolute detection limit ofthe instrument for 14C is 1 part 14C/1015 total carbon. The natural abundance of 14C in biological matter is 1 part 14C/1012 total carbon, which is two orders ofmagnitude above what can be routinely measured by AMS. In an effort to further increase our ability to measure macromolecular damage at low dose, we have attempted to reduce the amount of 14C present naturally in our animal models. Mice fed on a diet containing yeast protein obtained from organisms grown on petroleum-derived methanol have 20% of the 14C present in contemporary biological matter. This decrease has been achieved within one generation of feeding the special diet and will result in a 5-fold increase in the sensitivity of biological AMS measurements. Low-dose DNA binding analysis with heterocyclic amines is currently underway using these animals.
PhIP Adduct Levels
PhIP-DNA adduct levels have been measured in the mouse by 32P-postabeling. Three adduct spots are evident in liver tissue at all doses tested, and two adduct spots were found in all other tissues (Fig. 4A) . The structural nature ofthese PhIP adducts is as yet undetermined. Incubation of reactive PhIP metabolites with 2 '-deoxynucleotide-3 '-monophosphates indicate that all three adduct spots are derived from deoxyguanosine (Fig. 4B) 
Conclusion
Determining the relationships between exposure, time, systemic dose, and dose to target tissues is critical for ascertaining the validity of biological markers. Here we have shown that the dietary carcinogen PhlP, at a dose equivalent to consumption of 200 g of cooked beef, is quickly absorbed and distributed to the tissues. Elimination is also very rapid. DNA adducts are present in many tissues and increase as a linear function of dose. Adduct formation at higher doses does not seem to correlate with target tissues for carcinogenesis, suggesting that adduct formation alone is not necessarily indicative of tumorigenicity. The linearity of the adduct dose-response curve reported here for PhIP and also earlier for 2-amino-3,8-dimethylimidazo [4,5- JAquinoxaline (6) suggests that no or a very low threshold exists for DNA damage and that DNA adduct levels are indicative of exposure. The levels at which DNA damage and that DNA adduct levels are indictive of exposure. The levels at which DNA damage translates into a significant biological effect need to be determined before adducts can be validated as markers for effect or risk. Further studies are in process to define the relationship between exposure, macromolecular damage, and biological effect at low doses.
